AI Chatbot-Enabled ePRO Symptom Monitoring and Self-Management for Early Cardiovascular-Kidney-Metabolic Syndrome
Sponsor: Taipei Medical University
Trial Details
| Condition | Cardiovascular Kidney Metabolic Syndrome |
| Intervention | AI chatbot-enabled nurse-led program.; Usual Care |
| Phase | NA |
| Status | Not_yet_recruiting |
| Participants | 72 |
| Est. Completion | 31 July 2027 |
| Last Updated | 11 May 2026 |
Primary Outcome
PROMIS-29 v2.1
Eligibility Criteria
Inclusion Criteria
Inclusion Criteria: * Adults ≥40 years * Classified as having stage CKM syndrome (stage 1-2) * Receiving outpatient care * Able to communicate in Mandarin/Taiwanese, and * Having access to a smartphone/tablet Exclusion Criteria: * End-stage kidney disease requiring dialysis or are listed for kidney transplantation * Have terminal illness (\<6 months life expectancy) * Have significant cognitive impairment * Currently enrolled in another interventional study targeting cardiovascular-kidney-metabolic syndrome or multimorbidity
Trial Sites
Countries
This content is for educational purposes for healthcare professionals only and does not constitute clinical advice. Clinical decisions should be based on individual patient assessment, current guidelines, and appropriate specialist consultation. Editorial Standards · Privacy Policy · Terms of Service